Mobile

A multi-centre randomized double blind 12-week study to assess the efficacy, safety and tolerability of QVA149 in patients with COPD who have moderate to severe airflow limitation Multicentričn...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003347-30

A multi-centre randomized double blind 12-week study to assess the efficacy, safety and tolerability of QVA149 in patients with COPD who have moderate to severe airflow limitation Multicentrična, randomizirana, dvojno slepa, 12-tedenska študija za oceno učinkovitosti, varnosti in prenosljivosti zdravila QVA149 pri bolnikih s KOPB z zmerno do zelo zmanjšanim pretokom zraka

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the superiority of QVA149 27.5/12.5 μg b.i.d. compared to monotherapy components, QAB149 27.5 μg b.i.d. and NVA237 12.5 μg b.i.d., in terms of standardized FEV1AUC0-12 at Week 12.

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens